Novocure Ltd

NVCR has broken key support in a Stage 4 environment, signaling accelerating downside. Medium-term bearish asymmetry is reinforced by support failure and lower highs/lows. Short-term, price is extended below declining EMAs and in oversold territory, suggesting risk of a countertrend bounce. Therefore, focus on trimming positions on rallies into resistance.

• ↑Q2 net revenue $184M (+16% YoY) driven by expanding patient base
• ↑Optune Pax launch for pancreatic cancer shows 74% disease control rate
• ↓Net loss $16M in Q2 and $136M YTD pressures cash flow